Prophylactic effect of lipoic acid against adriamycin-induced peroxidative damages in rat kidney.
Adriamycin (ADR), which is widely used in the treatment of various neoplastic conditions, exerts toxic effects in many organs. The present study was designed to investigate the effect of lipoic acid (LA) against acute ADR induced peroxidative damages in rat kidney. The study was carried out with adult male albino rats of Wistar strain, which comprised of one control and three experimental groups. Group I rats served as controls. Group II rats received ADR (7.5mg/kg body weight) intravenously through the tail vein. Group III rats were given LA (75 mg/kg body weight) intraperitoneally. Group IV rats were given LA one day before the administration of ADR. Rats subjected to ADR administration showed a decline in the thiol capacity of the cell accompanied by high malondialdehyde (MDA) levels along with lowered activities of catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) glutathione (GSH) and GSH metabolizing enzymes (glutathione reductase (GR), glucose-6-phosphate dehydrogenase (G6PD)). However no significant change was observed in the activity of glutathione-S-transferees (GST). Pretreatment with LA showed considerable changes over oxidative stress parameters. Nephrotoxic damage was evident from the decrease in the activities of gamma-glutamyl transferase (gamma-GT) and beta-glucuronidase (beta-GLU), which were reverted upon LA pretreatment.


CONCLUSIONS
This study has highlighted the beneficial effects of LA pretreatment in reversing the damages caused by ADR, by bringing about an improvement in the reductive status of the cell.
Malarkodi
Kumaravel Palanichamy
KP
Department of Medical Biochemistry, Dr. A.L.M., Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, India.
Balachandar
Andithangal Venkatesan
AV
Sivaprasad
Rajagopalan
R
Varalakshmi
Palaninathan
P
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000975:Antioxidants / Q000494:pharmacology*; D002374:Catalase / Q000187:drug effects / Q000378:metabolism; D004317:Doxorubicin / Q000009:adverse effects*; D005609:Free Radicals / Q000009:adverse effects; D005954:Glucosephosphate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D005966:Glucuronidase / Q000187:drug effects / Q000378:metabolism; D005978:Glutathione / Q000187:drug effects / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000187:drug effects / Q000378:metabolism; D005980:Glutathione Reductase / Q000187:drug effects / Q000378:metabolism; D005982:Glutathione Transferase / Q000187:drug effects / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D023421:Models, Animal; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000187:drug effects / Q000378:metabolism; D008063:Thioctic Acid / Q000494:pharmacology*; D005723:gamma-Glutamyltransferase / Q000187:drug effects / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D005609:Free Radicals; D008063:Thioctic Acid; D004317:Doxorubicin; D005954:Glucosephosphate Dehydrogenase; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D005723:gamma-Glutamyltransferase; D005982:Glutathione Transferase; D005966:Glucuronidase; D005978:Glutathione